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hDepartment of Neurology, Baylor College of Medicine, Houston, TX, USAAbstract Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) and homocysteine (Hcy) havehttp://dx.doi.org/10.10
2352-8729/ 2015 T
license (http://creativebeen linked to inflammation and Alzheimer’s disease (AD). Using a case-control design, we exam-
ined their independent effects and interactions with cardiovascular disease equivalent (CVDE), on
AD risk.
Methods: AD cases and controls were from the Texas Alzheimer’s Research and Care Consortium
study. Lp-PLA2 was determined using the PLAC test (diaDexus, Inc), and Hcy by recombinant
cycling assay (Roche Hitachi 911). Logistic regression was used to predict AD case status. We as-
sayed for Lp-PLA2 in the brain tissue of cases and controls.
Results: AD case status was independently associated with Lp-PLA2 and Hcy above the median
(odds ratio [OR] 5 1.91; 95% confidence interval [CI] 5 1.22–2.97; P , .001 and OR 5 1.81;
95% CI 5 1.16–2.82; P 5 .009, respectively). Lp-PLA2, but not Hcy, interacted with CVDE to
increase risk. Lp-PLA2 was absent from the brain tissue in both groups.
Discussion: Higher Lp-PLA2 and Hcy are independently associated with AD. The association of Lp-
PLA2 with AD may be mediated through vascular damage.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Lp-PLA2; Homocysteine; Dementia; Biomarkers1. Introduction
It is widely accepted that inflammation plays an impor-
tant role in the pathogenesis of Alzheimer’s disease (AD)
[1,2] and in cardiovascular disease (CVD) [3,4]. Although
there are numerous reports on the relationship between
various inflammatory markers and AD [2,5], the
association of lipoprotein-associated phospholipase A2
(Lp-PLA2) with AD is far less known [6,7]. Lp-PLA2 is a16/j.dadm.2015.08.001
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).proinflammatory enzyme that circulates in plasma in active
form as a complex with low (LDL) and high (HDL) density
lipoproteins and, to a lesser extent, with lipoprotein (a) [8]. It
is primarily produced by macrophages and other inflamma-
tory cells, such as activated bone marrow–derived mast cells
and activated platelets [9]. Elevated levels of Lp-PLA2 indi-
cate increased oxidative stress and inflammation. Lp-PLA2
is well recognized as both an inflammatory marker and a
risk factor for coronary heart disease, stroke, and CVDimer’s Association. This is an open access article under the CC BY-NC-ND
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quires far more research, especially as it relates to the mech-
anisms by which Lp-PLA2 may influence the risk of AD and
how Lp-PLA2 relates to prevalent CVD and other risk fac-
tors in its association with AD.
Another risk factor implicated in the etiology of both AD
and CVD is homocysteine (Hcy), a sulfur-containing amino
acid produced in the methionine cycle and regulated by
vitamin-B12 and folic acid [11–13]. Epidemiologic studies
have shown that the abnormal elevation of circulating Hcy
increases the risk of AD [12]. In a study by Seshadri et al.
[12], among persons 60 years with Hcy levels .14 mM,
the risk of AD was almost double the risk among those
with lower Hcy. Conflicting results from clinical trials de-
signed to examine whether B-vitamin and folic acid therapy
may reduce Hcy and lower the risk of CVD and AD have
prompted the question of whether Hcy is a risk factor in
the etiology of AD or is just a marker of AD, reflecting the
actions of other risk factors [14]. It is also less known
whether CVD and other risk factors interact with Hcy in
affecting the risk of AD.
Research regarding the precise role of Lp-PLA2 and
Hcy in the occurrence of AD is complex and complicated
by the fact that AD and CVD often co-exist and share some
common risk factors including Lp-PLA2 and Hcy. Lp-
PLA2 and Hcy may affect the pathogenesis of AD (1)
directly and independently by affecting synaptic and
neuronal function, formation of amyloid plaques, and
neurofibrillary tangles; (2) interacting with each other in
increasing the risk of AD; and (3) indirectly increasing
vascular damage and promoting neurodegeneration with
loss of cognitive reserve [15].
To further explore the association of Lp-PLA2 and Hcy
with AD, we have analyzed data collected from AD patients
and cognitively normal controls enrolled in the Texas Alz-
heimer’s Research and Care Consortium (TARCC) study.
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two variables will not interact in their association with
AD, and (3) prevalent CVD and/or risk factors, such as hy-
pertension, cigarette smoking, and diabetes mellitus, will
interact with Lp-PLA2 and Hcy to modify the association
of Lp-PLA2 and Hcy with AD. To examine if the association
of Lp-PLA2 with AD was because of a central (brain meta-
bolism of lipids or brain injury) and/or peripheral (systemic
lipid metabolism, vascular damage) effect, we examined his-
topathologically brains of AD cases and nondemented con-
trols from the brain bank of the Alzheimer’s Disease and
Memory Disorders Center, Baylor College of Medicine,
Houston, TX, USA. Because we found no literature reports
on the presence of Lp-PLA2 in the brain, we hypothesized
that the association between Lp-PLA2 and AD is mediated
through peripheral lipid metabolism and vascular disease.2. Methods
2.1. Study population
TARCC was established in 1999 and initially included
four institutions: Texas Tech University Health Science Cen-
ter, the University of North Texas Health Science Center, the
University of Texas Southwestern Medical Center at Dallas,
and Baylor College of Medicine, Houston, TX, USA. The
University of Texas Health Science Center at San Antonio
and Texas A&M University were added in 2008 and 2013,
respectively. The main goal of the Consortium was to
develop a longitudinal cohort study of AD patients and
cognitively unimpaired controls, examined and followed
up annually at the participating institutions [16].
2.2. Study design
In the present report, a case-control study design was used
to examine variables of interest and their associations with
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using a standard protocol and had a laboratory panel and
neuropsychological assessments completed as of May
2010. Diagnoses were assigned during a consensus review
using National Institute of Neurological and Communicative
Disorders and Stroke-Alzheimer’s Disease and Related
Disorders Association (NINCDS-ADRDA) criteria [17].
Inclusion criteria for AD cases were men and women
50 years with a diagnosis of probable AD residing in Texas
or surrounding states with available information regarding
the duration of symptoms, who were willing to provide
blood specimens, had a reliable surrogate, and who agreed
to follow-up. Patients with a Hachinski score of.4, history
of major cortical infarction or lacunar infarct(s) in a critical
area, and/or persistent focal neurologic deficit were
excluded. Also excluded were individuals with neurologic
diseases that could contribute to the dementia (Parkinson
disease, dementia with Lewy bodies, and multiple sclerosis);
active cancer within the past 5 years (nonmelanoma skin
cancer and nonmetastatic prostate cancer were allowed);
depression or other psychiatric or systemic disorders that
could impact cognition (e.g., vitamin-B12 deficiency,
thyroid disorders, normal pressure hydrocephalus); and indi-
viduals using systemic steroids, chemotherapy, or anti-
inflammatory drugs (except nonsteroid drugs). Controls
were cognitively normal men and women aged 50 years
within the same residential areas as AD cases, with clinical
dementia rating (CDR) global score of 0 and CDR sum of
box score of 0, with normal cognition and function based
on the information provided by a reliable informant, and
who were willing to provide blood specimens and commit
to follow-up visits. Controls were judged to be cognitively
normal based on neuropsychological testing and in a
consensus review and could not be first-degree biological
relatives of TARCC patients. Individuals with a primary
neurologic disease or psychiatric illness and who used psy-
choactive medications in amounts that would be expected
to compromise cognition were excluded. Subjects with a
mild head injury without evidence of residual cognitive
impairment; medically controlled chronic diseases such as
diabetes mellitus, hypertension, and thyroid disease; and
depression not active at the time of examination were al-
lowed. The recruitment methodology did not call for cases
and controls to be formally matched on demographic or
other variables.2.3. Clinical and neuropsychological measurements
The protocol was approved by the institutional review
boards at each participating institution and informed consent
obtained for all participants. All clinical assessments were
part of the standard clinical work-up. Demographic charac-
teristics (age, sex, race, ethnicity, marital status, primary
language, handedness, years of education, living arrange-
ments, and zip code) and extensive medical history and
medication use were taken, also including physician’s esti-mate of disease duration [18]. Vital signs and assessment
of vision and hearing were also documented. Neuropsycho-
logical testing included examination of global cognitive
functioning status, with mini-mental state examination
(MMSE) [19] and CDR [14,20]; attention with digit span
[21,22] and Trials A [23]; executive function, with Trials
B [23] and CLOX I and II [24]; memory, with Wechsler
memory scale (WMS) logical memory I and II [21], the Con-
sortium to Established a Registry for Alzheimer’s disease list
learning and recognition [25]; language, with Boston
naming test [26], FAS verbal fluency [25] and animal
naming [25]; premorbid IQ, with the American version of
the Nelson Adult Reading Test (AMNART) [27,28];
visuospatial memory, with WMS-visual reproduction I and
II [21], psychiatric status, with geriatric depression scale
[29] and neuropsychiatric inventory questionnaire [30];
and functional status, with Lawton-Brody activities of daily
living: Physical Self-Maintenance Scale (PSMS), and instru-
mental activities of daily living scale [31]. Full spelling of all
abbreviations may be found in corresponding references.2.4. Laboratory analyses
Blood samples were taken at the time of entry into the
study. For biomarkers analyses, including C-reactive protein
(CRP), TARCC uses the technology offered by Rules-Based
Medicine, called multi-analyte profiles, a large panel of tests
that provide accurate and precise measurements of
numerous biological markers of inflammation [32]. This
approach reduces interassay variability, which is an impor-
tant methodological problem facing many comparable
studies. Lp-PLA2, Hcy, and lipid profile were measured at
the Maria and Alando J. Ballantyne Atherosclerosis Clinical
Research Laboratory at Baylor College of Medicine, Hous-
ton, TX, USA. Lp-PLA2 was determined using the diaDexus
PLAC test (diaDexus, Inc, San Francisco, CA), a dual mono-
clonal antibody immunoassay for the quantitative (mass)
determination of Lp-PLA2. Hcy levels were measured using
the recombinant cycling assay (Hitachi 911 analyzer; Roche
Diagnostics, Indianapolis, IN, USA). To assess reliability of
the Lp-PLA2 and Hcy measurements, we calculated corre-
sponding coefficients of variation (CV). For Lp-PLA2, intra-
assay (within run) CV was 3.6% and interassay (between
runs) CV was 5.7%. The intraassay and interassay CVs for
Hcy were 1.4% and 4.4%, respectively.2.5. Histopathologic assessments
Formalin-fixed, paraffin-embedded (FFPE) brain sec-
tions cut at 7 m of 10 deceased AD patients from the
TARCC cohort and 10 nondemented controls from the
Department of Pathology of the Methodist Hospital in
Houston, TX, USAwere obtained. Sections included cortex
(frontal, parietal, occipital, cingulate gyrus, and hippocam-
pus), brainstem (midbrain, pons, and medulla), cerebellum,
basal ganglia, amygdala, thalamus, and pituitary gland. The
Table 1
Baseline characteristics* of AD cases and controls
Characteristics
AD cases
(n 5 197)
Controls
(n 5 198) P value
Age at visit (y) 77.41 (8.29) 70.42 (8.89) ,.001
Sex (% male) 34.52 31.82 .75
BMI 25.68 (5.06) 27.43 (4.81) ,.001
MMSE 19.18 (6.22) 29.42 (0.88) ,.001
Lp-PLA2 (ug/L) 297.0 (71.6) 281.11 (65.7) .02
Median (IQR) 300.08 (83.65) 276.20 (94.40) .02
Homocysteine (u/M) 16.21 (9.01) 13.3 (5.03) ,.001
Median (IQR) 14.30 (8.75) 12.20 (6.30) ,.001
CRP (ug/mL) 3.23 (4.87) 3.68 (4.14) .32
Cholesterol (mg/L) 210.12 (50.11) 209.35 (62.04) .40
CVDEy 48.22 46.46 .73
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blocks per case were prepared, 10 sections cut on each
block, to assure adequate material for examination. Frozen
tissues were also cut and results compared with those of the
FFPE tissue. Standard immunochemical procedures were
used using Dako immunohistochemical automated stainers
and staining of individual slides by hand in parallel [33].
Catalyzed signal amplification system Dako code K1500
was used to develop/stain slides. Automated and hand
staining were performed on the FFPE materials and on
the frozen material as well using an antibody to
Lp-PLA2 from diaDexus (Lp-PLA2 Monoclonal AB 4b4
PN: 2611 LN: 1012103) using a dilution of 1:2500. Multi-
ple dilutions were attempted in parallel.Abbreviations: AD, Alzheimer’s disease; BMI, body mass index (calcu-
lated as weight in kilograms divided by the square of height in meters);
MMSE, mini-mental state examination; Lp-PLA2, lipoprotein-associated
phospholipase A2; IQR, interquartile range; CRP, C-reactive protein;
CVDE, cardiovascular disease equivalent; CHD, coronary heart disease.
*Unadjusted mean values (standard deviations) or proportions.
yCVDE calculated according to the Adult Treatment Panel III guidelines
[34] (history of myocardial infarction, stent placement, congestive heart
failure, diabetes, or increased risk of CHD with any two of hypertension,
hyperlipidemia, or current cigarette smoking).
Table 22.6. Statistical analyses
Means and standard deviations of continuous variables
and proportions of binary variables at baseline were
compared in AD cases and controls. We also determined me-
dian values and interquartile range for Lp-PLA2 and Hcy.
Fisher’s exact test (unadjusted) and multivariable (adjusted)
models were used to analyze the association of Lp-PLA2,
Hcy, and other baseline characteristics with AD status
(case vs. control). In assessing the association of Lp-PLA2
and Hcywith AD status, Lp-PLA2 and Hcy were used as cat-
egorical variables, dichotomized at the median value
because their values were very skewed. AD status (case vs.
control) was used as the outcome variable and Lp-PLA2
and Hcy (above vs. below median) as independent variables.
The lower category (Lp-PLA2 and Hcy levels below me-
dian) served as referent with which the upper category
(above median) was compared. We also examined potential
interactions of Lp-PLA2 and Hcy with each other and with
prevalent CVD and/or CVD risk factors, using a variable
defined as cardiovascular disease equivalent (CVDE). The
CVDE was calculated according to the National Cholesterol
Education Program—Adult Treatment Panel III guidelines
(history of myocardial infraction, stent placement, conges-
tive heart failure, diabetes mellitus, or high risk for CHD
with any two of hypertension, hyperlipidemia, or current
cigarette smoking, as categorical variables) [34]. To control
for potential confounding, all models included adjustment
for age, sex, and body mass index (BMI). All statistical an-
alyses were performed using the SAS statistical package,
version 8 (SAS Institute Inc, Cary, NC, USA).Adjusted* odds ratio of Alzheimer’s disease in relation to Lp-PLA2 valuesy
Variables Odds ratio* 95% CI P value
Lp-PLA2 1.91 1.22–2.97 ,.001
Age (y) 1.09 1.06–1.24 ,.0001
Sex (M vs. F) 1.29 0.80–2.07 .29
BMI 0.97 0.93–1.02 .26
Abbreviations: Lp-PLA2, lipoprotein-associated phospholipase A2; CI,
confidence interval; M, male; F, female; BMI, body mass index.
*Adjusted for age, sex, and body mass index.
yValues dichotomized at median, odds ratio for values above median.3. Results
The baseline characteristics of AD cases and controls are
listed in Table 1. AD cases were significantly older and, as
expected, had lower MMSE scores and lower BMI. In our
analyses, we used age as a continuous variable, but it should
be noted that 8.1% of cases and 29.9% of controls were aged
,65 years. There was no statistically significant difference
in the proportion of men among AD cases versus controlsor in the proportion of AD cases and controls with prevalent
CVDE. Also, there was no statistically significant difference
in the mean values of CRP and total cholesterol levels be-
tween cases and controls. Unadjusted mean values of both
Lp-PLA2 and Hcy were significantly higher among AD
cases than among controls (P , .02 and P , .001, respec-
tively). Median values of Lp-PLA2 and Hcy were also
significantly higher among AD cases than among controls.
To assess the association of Lp-PLA2 and Hcy with AD,
we dichotomized all values (including cases and controls)
at median, which was for Lp-PLA2 293.1 and for Hcy
13.1 mM. About 60% of AD cases had Lp-PLA2 or Hcy
levels above the median versus about 40% among controls
for both variables. Odds ratio (OR) of AD in relation to
Lp-PLA2 levels is listed in Table 2. After adjustment for
age, sex, and BMI, subjects with Lp-PLA2 levels above
the median were almost twice as likely to have AD than
those with levels below the median (OR 5 1.91,
P , .0001). The likelihood of having AD among subjects
with higher Hcy levels was also greater compared with the
Table 3
Adjusted* odds ratio of Alzheimer’s disease in relation to homocysteine
valuesy
Variables Odds ratio* 95% CI P value
Homocysteine 1.81 1.16–2.82 .009
Age (y) 1.09 1.16–2.82 ,.0001
Sex (M vs. F) 1.21 0.75–1.93 .44
BMI 0.96 0.91–1.01 .08
Abbreviations: CI, confidence interval; M, male; F, female; BMI, body
mass index.
*Adjusted for age, sex, and body mass index.
yValues dichotomized at median, odds ratio for values above median.
Table 5
Adjusted* odds ratio of Alzheimer’s disease in relation to CVDE and
homocysteine
Variables Odds ratio 95% CI P value
CVDE 0.78 0.49–1.24 .29
Homocysteiney 1.89 1.20–2.97 .01
Age (y) 1.09 1.06–1.12 ,.0001
Sex (M vs. F) 1.23 0.77–1.98 .38
BMI 0.97 0.92–1.01 .14
Abbreviations: CVDE, cardiovascular disease equivalent [34]; CI, confi-
dence interval; M, male; F, female; BMI, body mass index.
*Adjusted for age, sex, and body mass index; the interaction term be-
tween CVDE and homocysteine is insignificant (P 5 .38).
yHomocysteine above median.
R.S. Doody et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 464-471468subjects with lower levels, with adjusted OR 5 1.81,
P 5 .009 (Table 3). To examine if there was an interaction
between Lp-PLA2 and Hcy, we included the interaction
term (Lp-PLA2 . median! Hcy . median) in the multi-
variate model and found no significant interaction between
the two variables (P 5 .78). We then examined possible in-
teractions between Lp-PLA2 and Hcy with CVDE. In a
multivariable model, we found a significant interaction be-
tween Lp-PLA2 and CVDE (P5 .02, Table 4). In the model
examining the contribution of CVDE, it was of borderline
significance regardless of Lp-PLA2 and Lp-PLA2 was not
an independent risk variable (P 5 .79). In a multivariate
model with Hcy and CVDE (Table 5), Hcy remained a sig-
nificant variable (P 5 .01) and the interaction term between
Hcy and CVDE was statistically insignificant (P 5 .38, not
listed in the table).
Histoimmunologic analyses of autopsy brain tissue were
performed on 10 AD cases (nine women and one man) and
10 controls (six women and four men).
Mean age of AD cases and controls was 79.2 and 72.5,
respectively. The results of Lp-PLA2 staining were negative
for both the FFPE and the frozenmaterial in all AD cases and
controls.Table 4
Adjusted* odds ratio of Alzheimer’s disease in relation to CVDE and Lp-
PLA2
Variables and interactions Odds ratio 95% CI P value
Lp-PLA2y! CVDE — — .02
CVDE — — .06
CVDE 5 1, Lp-PLA2y 1.72 0.89–3.34 —
CVDE 5 0, Lp-PLA21 0.53 0.27–1.02 —
Lp-PLA2 — — .79
Lp-PLA2y, CVDE 5 1 3.56 1.08–6.99 —
Lp-PLA21, CVDE 5 0 1.08 0.59–2.02 —
Age (y) 1.10 1.07–1.113 ,.001
Sex (M vs. F) 1.30 0.80–2.09 .29
BMI 0.98 0.93–1.03 .40
Abbreviations: CVDE, cardiovascular disease equivalent [34]; Lp-PLA2,
lipoprotein-associated phospholipase 2; CI, confidence interval; Lp-PLA2
! CVDE, interaction term; CVDE 5 1, CVDE present; CVDE 5 0,
CVDE absent; M, male; F, female; BMI, body mass index.
*Adjusted for age, sex, and body mass index.
yLp-PLA2 above median, 1Lp-PLA2 below median.4. Discussion
The results of our study showed that in the TARCC
cohort, after adjustment for age, sex, and BMI, higher levels
of both Lp-PLA2 and Hcy were significantly associated with
prevalent AD. Subjects with higher levels of Lp-PLA2 were
almost twice as likely to have AD compared with subjects
with Lp-PLA2 levels below the median. We found a signif-
icant interaction between prevalent CVDE and Lp-PLA2. In
the model which included the interaction term, prevalent
CVDE remained a significant and independent variable,
whereas Lp-PLA2 was no longer an independent factor in
the prevalence of AD. This would suggest that the associa-
tion of Lp-PLA2 with AD might be primarily mediated
through CVDE.
The relationship between Lp-PLA2 and AD reported in
other studies has been inconsistent. The prospective Rotter-
dam study [6] showed that higher levels of Lp-PLA2 were
associated, independent of other CVD and inflammatory
factors, with increased risk of dementia in general but not
with AD in particular. The prospective Framingham Study
showed that, after adjustment for other risk factors, Lp-
PLA2 was not a significant risk factor for all-cause dementia
or AD [35]. The authors proposed that this lack of associa-
tion between Lp-PLA2 and AD could be because of a rela-
tively small number of incident AD cases in the sample
and the age of the participants at which Lp-PLA2 was
measured. The authors also suggested that Lp-PLA2 levels
in the blood might not reflect concentrations in the brain tis-
sue or in the cerebrospinal fluid [35]. Similarly to our find-
ings, the most recently published findings from the
prospective Cardiovascular Health Study [36] showed that
increased levels of Lp-PLA2 were associated with an
increased risk of AD. Contrary to our findings, however,
this association was independent of the presence of CVD
morbidity or CVD risk factors. The authors concluded that
Lp-PLA2 may be an important predictor of AD, without or
with concurrent vascular dementia. The discrepancy be-
tween our findings and the findings from the Cardiovascular
Health Study may be explained by different study designs,
ascertainment, and potential misclassification of the
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where the number of cases of vascular dementia was very
small, and the number of variables used in the adjusted
models to determine OR or hazard ratio of AD in these
two studies. In a small cross-sectional study of 78 AD cases,
59 amnestic mild cognitive impairment cases, and 66 cogni-
tively normal controls, Davidson et al. [7] found no signifi-
cant association between Lp-PLA2 activity and AD. In that
study, the main clinical correlates of Lp-PLA2 activity in
AD cases and controls were lipid levels and statin use.
One large genetic case-control study conducted in Japan
showed that inherited deficiency of Lp-PLA2 activity, due
to carriage of the V279F null allele, was not associated
with a reduced risk of AD [37].
Extensive basic research into the role of Lp-PLA2 in the
pathogenesis of atherosclerosis and in clinical manifesta-
tions of CVD [3,4,9] is mainly focused on the role of Lp-
PLA2 in oxidative stress, inflammation, cardiometabolic
risk, and on modulation of Lp-PLA2 [9]. Lp-PLA2 is a pro-
moter of inflammation, a critical feature of the atheroscle-
rotic process.
A meta-analysis of 32 prospective studies showed that
both Lp-PLA2 mass and activity were related to proathero-
genic lipids and vascular risk [4]. Because Lp-PLA2 binds
with both LDL and HDL, it is possible that Lp-PLA2 ex-
hibits a dual action, depending on its association with proa-
therogenic LDL or antiatherogenic HDL. This might
provide an opportunity for manipulation of Lp-PLA2 modu-
lation, by means of medications and diet [9].
Our results suggest that the association of Lp-PLA2 with
AD might be largely mediated through the prevalent CVDE.
This would imply the same biological plausibility of the Lp-
PLA2-AD and Lp-PLA2-CVD relationship. This was also
supported by our histopathologic analysis: we did not find
Lp-PLA2 in the brain tissue of AD cases or controls. All
this suggests that peripheral lipid metabolism and vascular
damage may be a key mediating mechanism by which Lp-
PLA2 predisposes to AD. These issues require further
research generated from prospective epidemiologic studies
and from histopathologic and other laboratory studies. Our
findings regarding the association between Hcy and AD
are consistent with the results of other epidemiologic and
clinical studies [12,38]. After adjusting for age, sex, and
BMI, ORs showed that AD cases were more likely to have
Hcy above the median than controls. The association
between increased Hcy and the occurrence of AD and
CVD may be linked to oxidative stress. About 80% of Hcy
present in human blood is bound with proteins. There is a
causal relationship between the levels of Hcy-bound proteins
and oxidative damage. An intramolecular hydrogen atom
mechanism provides biochemical rationale for the link be-
tween protein oxidation and Hcy [11,39]. Experimental
studies have also shown that Hcy promotes oxidative stress
via generation of reactive oxygen species (ROS) on
disulfide bond formation [39]. An interesting finding is
that cysteine is more abundant than Hcy and also undergoesdisulfide- and ROS-forming reactions but it is not associated
with these diseases. This has prompted further research to
find potential alternativemechanisms of Hcy action different
from those found in the case of cysteine, glutathione, and
other biological thiols [39]. Hcy metabolism is regulated
by folic acid and vitamin-B12 [40]. Kruman et al. [40] re-
ported that low folic acid and elevated Hcy may promote
accumulation of DNA damage, affect DNA repair in neu-
rons, and sensitize them to amyloid beta protein (A-beta)
toxicity. Another explanation offered by Zhang et al. [13] in-
cludes the effect of elevated Hcy in enhancing expression of
gamma-secretase and its effect on A-beta phosphorylation,
leading to overproduction of A-beta. The authors suggested
that high Hcy may serve as an “upstream” factor for
increased A-beta production as seen in patients with AD.
Further basic research is critical for explaining the mecha-
nism of action of high Hcy, especially in the light of incon-
sistencies in findings of clinical trials aimed at Hcy lowering
by means of B-vitamin and folic acid therapy to reduce AD
and CVD risk. We found no interaction between Lp-PLA2
and Hcy in their association with AD. We also did not find
a significant interaction between CVDE and Hcy suggesting
differences in mechanisms by which these two variables
affect the risk of AD. One longitudinal epidemiologic study
showed that Hcy is significantly and independently associ-
ated with the incidence of AD but not with the incidence
of vascular dementia [41] whereas, as shown previously,
Lp-PLA2 association with AD seems to be predominantly
mediated via vascular damage.
One of the disadvantages of our study is its retrospective
case-control design, with all limitations regarding the cause-
effect examination. This concern is mitigated by the pro-
spective nature of the systematic data collection for TARCC
study which will allow for analyses of the association be-
tween Lp-PLA2 and the incidence and the rate of progres-
sion of AD. This also applies to other inflammatory
biomarkers measured in the TARCC cohort, and it is ad-
dressed in another article in preparation by the same group
of investigators.5. Conclusions
There is limited evidence that Lp-PLA2 is a significant
and independent risk factor for AD. It is likely that the rela-
tionship between Lp-PLA2 and AD is mediated primarily
via CVDE. The association of higher levels of Hcy with
the prevalence of AD seems to be independent of CVDE.
Further research in these areas is of great importance
because Lp-PLA2 and Hcy are modifiable risk factors and,
if further confirmed, they may be considered as therapeutic
targets in preventing AD and in reducing severity of AD.Acknowledgments
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1. Systematic review: An extensive literature search
was conducted using PubMed, covering the areas
of basic science, clinical, and epidemiologic aspects
of the association between lipoprotein-associated
phospholipase 2 (Lp-PLA2), homocysteine, and
Alzheimer’s disease (AD). The literature concerning
the relationship between Lp-PLA2 and AD, partic-
ularly mechanism of action, is relatively scarce
compared with that of other biomarkers.
2. Interpretation: Our findings add to the evidence of
increased risk of AD associated with higher levels
of Lp-PLA2 and homocysteine. These two vari-
ables were independently associated with AD. The
relationship between Lp-PLA2 and AD may be
mediated via vascular damage, which is consistent
with our finding that Lp-PLA2 is absent in the brains
of both AD cases and controls.
3. Future directions: To establish firmly the role of Lp-
PLA2 in the etiology of AD, confirmation of these
findings is needed in prospective studies with a larger
number of AD cases. This is important because of the
potential utility of Lp-PLA2 in the early detection
and progression of AD.
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